Pancreatic Cancer Research

ResearcherSichuan UniversityNo recent work listed

Shengyong Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5147-3746; OpenAlex author ID A5069425796. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
6
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper

Papers 3

  1. Discovery of Potent Small-Molecule SIRT6 Activators: Structure-Activity Relationship and Anti-Pancreatic Ductal Adenocarcinoma Activity. Last author DOI 10.1021/acs.jmedchem.0c01183↗
  2. Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.13929↗
  3. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer. Last author DOI 10.1158/1535-7163.mct-14-0485↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiuli Chen · 1 shared paper, 2020 · strength 0.11
  2. Bing Peng · 1 shared paper, 2019 · strength 0.09
  3. Linli Li · 1 shared paper, 2019 · strength 0.09
  4. Lingwei Meng · 1 shared paper, 2019 · strength 0.09
  5. Wei Yang · 1 shared paper, 2019 · strength 0.09
  6. Youli Pan · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.